Among the data from phase 2 studies using finerenone have been available, but three clinical trials (ARTS (minerAlocorticoid Receptor Antagonist Tolerability Study) [68], ARTS-HF [69], and ARTS-HF Japan [70]) have investigated cardiovascular outcomes in patients with HFrEF with chronic kidney disease (CKD) or diabetes mellitus. Here, NR3C2 is linked to chronic kidney disease.